TGTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TG

Mkt Cap

$8.26B

Volume

1.32M

Next Earnings

November 2nd

Loading chart

TG

TGTXTG Therapeutics, Inc.

TGTX

Pay with—

Available Balance0.00

TG

Mkt Cap

$8.26B

Volume

1.32M

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

TGTX Stock Rises 60% in 6 Months: Here's What You Should KnowTG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.Zacks Investment Research · Oct 13, 2026

Thermo Fisher to Report Q3 Earnings: What's in the Cards?Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion.Zacks Investment Research · Oct 13, 2026

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?TG Therapeutics shares have gained 15.1% since its last earnings report in early September 2026. While the company beat revenue expectations with $240.3M (up 70.3% YoY) driven by strong Briumvi sales, it missed EPS estimates at $0.05 vs. $0.41 expected. The company raised its 2026 revenue guidance to ~$950M. However, analyst estimates have trended downward since the report, and the stock received a Zacks Rank #3 (Hold) with poor Growth and Momentum scores, suggesting limited upside ahead.Zacks Investment Research · Sep 2, 2026

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of TG Therapeutics breached fiduciary duties to shareholders through potential self-dealing. The firm is seeking long-term TGTX stockholders to participate in shareholder litigation, offering free consultations with no obligation.GlobeNewswire Inc. · Jul 17, 2026

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple SclerosisTG Therapeutics announced a collaboration with actress Christina Applegate, who has lived with MS for 5 years, to raise awareness and support meaningful conversations for people living with multiple sclerosis. The partnership launched a new platform called www.NextInMS.com during Super Bowl LX, featuring Christina's personal perspectives and expert educational content designed to foster open dialogue among MS patients, caregivers, and healthcare professionals.GlobeNewswire Inc. · Feb 8, 2026

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Tumble Ahead Of SC Ruling On Trump's Tariffs— Wells Fargo, BP, WeRide In Focus (UPDATED)U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trading. Notable movers include Wells Fargo reporting earnings, BP announcing a $5 billion writedown in energy transition businesses, WeRide launching a robotaxi service on WeChat, and TG Therapeutics providing optimistic 2026 guidance.Benzinga · Jan 14, 2026

TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation SummitTG Therapeutics' CEO Michael S. Weiss will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit on November 12, 2025, discussing the company's developments in B-cell disease treatments.GlobeNewswire Inc. · Nov 10, 2025

TG Therapeutics Q2 Revenue Up 91%TG Therapeutics reported strong Q2 2025 results with BRIUMVI sales growth, raising full-year revenue guidance to $585 million. The company is focusing on expanding product reach, developing new dosing regimens, and exploring additional indications for its multiple sclerosis therapy.The Motley Fool · Aug 4, 2025

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue GuidanceTG Therapeutics reported strong Q1 2025 financial results for its multiple sclerosis drug BRIUMVI, with $119.7 million in U.S. net sales and raised its full-year revenue guidance. The company also provided updates on its pipeline, including plans to advance subcutaneous BRIUMVI and a new therapy for progressive MS.GlobeNewswire Inc. · May 5, 2025

Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?Several mid-cap stocks, including Bilibili, MARA Holdings, and ZEEKR Intelligent Technology, saw significant gains last week. The article highlights the top 8 mid-cap gainers and discusses the reasons behind their performance.Benzinga · Mar 9, 2025

to start trading

TG

TGTXTG Therapeutics, Inc.

TGTX

Pay with—

Available Balance0.00

Your PositionYou don't own any TGTX yet.

Related Tickers

Earnings